Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease

The aim of the present study was to compare the effects of gliclazide, liraglutide, and metformin in type 2 diabetes mellitus (T2DM) patients with non‐alcoholic fatty liver disease (NAFLD).

[1]  J. Holst,et al.  Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference , 2016, Diabetes Care.

[2]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[3]  Farhad Zamani,et al.  Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. , 2016, World journal of gastroenterology.

[4]  H. Bian,et al.  I148M variant of PNPLA3 increases the susceptibility to non‐alcoholic fatty liver disease caused by obesity and metabolic disorders , 2016, Alimentary pharmacology & therapeutics.

[5]  Rachel M. Brown,et al.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.

[6]  Qianyue Xu,et al.  Comparative efficacy of anti‐diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis of randomized and non‐randomized studies , 2016, Diabetes/metabolism research and reviews.

[7]  W. Wahli,et al.  Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD , 2016, Gut.

[8]  A. Marcadenti,et al.  Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease , 2015, Journal of diabetes research.

[9]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[10]  Xin Gao,et al.  Assessment of liver fat content using quantitative ultrasonography to evaluate risks for metabolic diseases , 2015, Obesity.

[11]  Dongfeng Chen,et al.  Non-alcoholic steatohepatitis-related liver cirrhosis is increasing in China: A ten-year retrospective study , 2015, Clinics.

[12]  A. Ido,et al.  Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies , 2015, Clinical Journal of Gastroenterology.

[13]  E. Kang,et al.  Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway , 2015, Autophagy.

[14]  J. Lavine,et al.  Review article: the management of paediatric nonalcoholic fatty liver disease , 2014, Alimentary pharmacology & therapeutics.

[15]  M. Hao,et al.  Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes , 2014, Diabetes/metabolism research and reviews.

[16]  Ming Li,et al.  Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes , 2014, Acta Diabetologica.

[17]  S. Alavian,et al.  Effects of a novel therapeutic diet on liver enzymes and coagulating factors in patients with non-alcoholic fatty liver disease: A parallel randomized trial. , 2014, Nutrition.

[18]  S. Reeder,et al.  Quantitative chemical shift‐encoded MRI is an accurate method to quantify hepatic steatosis , 2014, Journal of magnetic resonance imaging : JMRI.

[19]  R. Scholten,et al.  The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta‐analysis , 2014, Diabetes/metabolism research and reviews.

[20]  K. Cusi,et al.  High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. , 2014, The Journal of clinical endocrinology and metabolism.

[21]  T. Saibara,et al.  Glycemic Variability Is an Independent Predictive Factor for Development of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease , 2013, PloS one.

[22]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[23]  Jiang He,et al.  Prevalence and control of diabetes in Chinese adults. , 2013, JAMA.

[24]  Christopher D Byrne,et al.  Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. , 2013, The Journal of clinical endocrinology and metabolism.

[25]  Hiroki Sato,et al.  Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus. , 2013, Internal medicine.

[26]  Meng-Su Zeng,et al.  Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method , 2011, Obesity.

[27]  Christopher D. Williams,et al.  Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12‐month randomized, prospective, open‐ label trial , 2011, Hepatology.

[28]  P. Hayes,et al.  Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.

[29]  N. Chalasani,et al.  Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series , 2010, The American Journal of Gastroenterology.

[30]  Corby K. Martin,et al.  Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes. , 2010, Journal of diabetes and its complications.

[31]  G. Cowin,et al.  Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. , 2009, Journal of hepatology.

[32]  T. Ueno,et al.  Nateglinide is useful for nonalcoholic steatohepatitis (NASH) patients with type 2 diabetes. , 2005, Hepato-gastroenterology.

[33]  S. Pattingre,et al.  The Evolutionarily Conserved Domain of Beclin 1 is Required for Vps34 Binding, Autophagy, and Tumor Suppressor Function , 2005, Autophagy.

[34]  A. Häkkinen,et al.  Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. , 2004, Diabetes.

[35]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .